Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for allegedly misleading investors regarding the performance of its North America Fiber Cement segment during the specified Class Period from May 20, 2025, to August 18, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that James Hardie misled investors about the strength of its key segment, despite knowing that distributors were destocking inventory [5]. - Investors who purchased common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm for more information [3][6]. - A lead plaintiff must be appointed by December 23, 2025, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has been ranked highly in the field since 2013 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1] Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit claims that defendants made false or misleading statements regarding the efficacy of their product compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased V.F. Corporation securities during the specified class period of the upcoming lead plaintiff deadline on November 12, 2025 [1] Group 1: Class Action Details - Investors who purchased V.F. Corporation securities between October 30, 2023, and May 20, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit alleges that V.F. Corporation's management provided misleading information regarding the company's turnaround plans, particularly concerning the Vans brand [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [4]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of CS Disco, Inc. [1] Group 1 - The investigation pertains to whether the officers and directors acted in the best interests of shareholders [1] - Shareholders who acquired CS Disco stock on or before July 21, 2021, may seek various forms of relief, including corporate governance reforms and financial incentives [1]

Core Points - DISCO will announce its third quarter 2025 financial results on November 5, 2025, after market close [1] - A conference call and webcast to discuss the financial results will take place at 4:00 p.m. Central Time on the same day [2] - The company provides innovative litigation technology solutions, leveraging AI to enhance legal processes [4] Financial Results Announcement - The financial results for the third quarter ended September 30, 2025, will be reported after market close on November 5, 2025 [1] - A conference call will be accessible via phone and webcast, with specific dial-in numbers and conference ID provided [2] Company Overview - DISCO is recognized for its cloud-native platform that supports modern litigation, combining technology with professional services [4] - The company aims to simplify complex legal tasks and improve outcomes for law firms and corporations [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2] - To serve as lead plaintiff, individuals must file a motion with the court by November 7, 2025 [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3] Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4] - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital [4] - The lawsuit asserts that the public statements made by the defendants were materially false and misleading, resulting in investor damages when the true information became public [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025, of the December 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 8, 2025, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Background - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper steroid usage, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of MoonLake Immunotherapeutics common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and statements [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that the defendants made false or misleading statements regarding the efficacy and clinical benefits of their product SLK compared to traditional monoclonal antibodies [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. - The Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]. - A lead plaintiff must move the Court by December 15, 2025, to represent other class members in the litigation [1][3]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - No class has been certified yet, meaning investors are not represented unless they retain counsel [7]. - Investors can choose to remain absent from the class and still have the potential to share in any future recovery [7].

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. common stock between July 29, 2024, and January 6, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The deadline to move the Court to serve as lead plaintiff is December 8, 2025 [3] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [4] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4] - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions for investors [4] Group 3: Case Allegations - The lawsuit alleges that Cepton's defendants made materially false and misleading statements regarding the company's business and operations [5] - Specific allegations include failure to disclose a credible third-party bid valuing Cepton at more than double the Koito Acquisition and the Board's failure to explore this offer [5] - As a result, shareholders were deprived of the opportunity to consider the Koito Acquisition meaningfully [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased KBR, Inc. securities between May 6, 2025, and June 19, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit set for November 18, 2025 [1]. Group 1: Class Action Details - Investors who bought KBR securities during the specified Class Period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by the November 18, 2025 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that KBR's defendants made materially false and misleading statements regarding the company's partnership with the U.S. Department of Defense's Transportation Command, which had concerns about HomeSafe's ability to fulfill a significant contract [5]. - As a result of these misleading statements, the lawsuit claims that investors suffered damages when the true details became public [5].